ARCHIVES

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

NCAB Working Group To Hold Open And Closed Sessions

January 20, 1995

FDA Recruiting ODAC Consumer Rep Candidates

March 31, 1995

Clearinghouse Completes Review of Backlog, Funds What Caused It, Reports On Program Value

May 19, 1978

Gore Proposes New War On cancer, Double research Funding Over 5 years

July 9, 1999

The Varmus Era: Controversy Continues

January 6, 1995

Former NCI, FDA Chief Andrew Von Eschenbach Appointed to NCCN Foundation Board

June 17, 2011